A Multicenter, Randomized, Phase III Registration Trial of Transplantation of NiCord, Ex Vivo Expanded, UCB-derived, Stem and Progenitor Cells, vs. Unmanipulated UCB for Patients With Hematological Malignancies
Phase of Trial: Phase III
Latest Information Update: 17 Apr 2018
At a glance
- Drugs Cord blood stem cell therapy (Primary)
- Indications Haematological malignancies
- Focus Registrational; Therapeutic Use
- Sponsors Gamida-Cell
- 11 Apr 2018 Planned End Date changed from 1 Dec 2019 to 1 Dec 2020.
- 11 Apr 2018 Planned primary completion date changed from 1 Dec 2018 to 1 Dec 2019.
- 18 Jun 2017 Planned End Date changed from 1 Aug 2019 to 1 Dec 2019.